State Board of Administration of Florida Retirement System Decreases Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

State Board of Administration of Florida Retirement System decreased its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Rating) by 22.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,370 shares of the company’s stock after selling 1,840 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Keros Therapeutics were worth $306,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in KROS. Barclays PLC lifted its stake in Keros Therapeutics by 187.7% in the third quarter. Barclays PLC now owns 97,575 shares of the company’s stock valued at $3,671,000 after buying an additional 63,658 shares during the last quarter. Tudor Investment Corp Et Al lifted its stake in Keros Therapeutics by 5.2% in the third quarter. Tudor Investment Corp Et Al now owns 12,829 shares of the company’s stock valued at $483,000 after buying an additional 636 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in Keros Therapeutics by 109.1% in the third quarter. Parkman Healthcare Partners LLC now owns 99,927 shares of the company’s stock valued at $3,759,000 after buying an additional 52,139 shares during the last quarter. Bank of Montreal Can purchased a new stake in Keros Therapeutics in the fourth quarter valued at approximately $933,000. Finally, Birchview Capital LP purchased a new stake in Keros Therapeutics in the fourth quarter valued at approximately $336,000. Hedge funds and other institutional investors own 64.14% of the company’s stock.

Wall Street Analyst Weigh In

KROS has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research note on Monday, March 6th. Cowen initiated coverage on Keros Therapeutics in a research note on Tuesday, February 14th. They set an “outperform” rating for the company. Cowen initiated coverage on Keros Therapeutics in a research note on Tuesday, February 14th. They set an “outperform” rating for the company. Finally, Piper Sandler cut their price target on Keros Therapeutics from $120.00 to $110.00 in a research note on Friday, May 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $103.75.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $48.78 on Monday. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -11.09 and a beta of 1.23. Keros Therapeutics, Inc. has a fifty-two week low of $24.38 and a fifty-two week high of $59.96. The stock’s fifty day moving average is $43.20 and its two-hundred day moving average is $47.94.

Keros Therapeutics (NASDAQ:KROS – Get Rating) last issued its quarterly earnings data on Thursday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.14) by ($0.12). During the same quarter last year, the firm posted ($1.01) earnings per share. As a group, sell-side analysts forecast that Keros Therapeutics, Inc. will post -5.44 EPS for the current fiscal year.

About Keros Therapeutics

(Get Rating)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis.